A c c e p t e d M a n u s c r i p t 5 CAR T cells persist longer. However, this has not translated in significant differences in clinical outcome. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A recent preclinical study directly comparing CD19.41BB.ζ and CD19.CD28.ζ CAR T cells has highlighted significant differences between CD28 and 41BB costimulation in CAR T cells.
[24] While CD28 signaling induced effector memory differentiation, and glycolytic metabolism, 41BB signaling preserved a central memory phenotype and induced mitochondrial biogenesis, resulting in an increase of oxidative metabolism and spare respiratory capacity. Whether or not the combination of CD28 and 41BB costimulation results in enhanced effector function of CAR T cells remains controversial and model dependent. However, one study suggests that expressing 41BBL on the cell surface of CD28.ζ CAR T cells results in superior effector function in comparison to CD28.ζ or 41BB.ζ CAR T cells by activating the IFN regulator factor 7 (IRF7) pathway.
[25] For GBM, preclinical and clinical studies have been conducted with ζ, CD28.ζ and 41BB.ζ CAR T cells. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] While initially the CAR spacer region and transmembrane domain were only considered a structural component of the CAR, several studies have highlighted their critical contribution to CAR function. [39, 40] The most frequently used spacers are derived from IgG1 hinge (12aa), or the CH2CH3 domain of IgG 1 or 4 (hinge and Fc domain, 229aa). [41, 42] Studies have demonstrated that the Fc domain interacts with cells expressing Fc gamma receptors (FcγR) in vivo, resulting in off-target activation and/or killing of CAR T cells by FcγR-positive innate immune cells. [40, 41, 43] In addition, a CH2CH3-based spacer can cause baseline (aka tonic) CAR signaling without cognate A c c e p t e d M a n u s c r i p t 8 needs to be performed. CD70 expression in high-grade gliomas can cause immunosuppression by inducing T-cell dysfunction and apoptosis, [50] and is associated with significant increase in tumor-associated macrophages. [51] Lastly, a recent study suggests that CD70 expression is involved in mediating tumor aggressiveness and immunosuppression through recruitment of tumor-associated macrophages. [52] 
EGFR and EGFRvIII
EGFR is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family). It is overexpressed in primary (63%) and secondary (10%) glioblastomas. [53] EGFR influences the migration of neural stem cells during development, and promotes cellular proliferation through activation of MAPK and PI3K-Akt pathways. [54] As for expression in normal tissue, EGFR is expressed in tissues of epithelial, mesenchymal and neuronal origin and plays a major role in normal cellular processes such as proliferation and differentiation. In GBM, EGFR expression frequently involves amplifications or alterations of the EGFR gene which results in expression of various mutations. The most common EGFR mutant variant found in GBM is EGFR variant 3 (EGFRvIII). It arises from mutated/gene amplified EGFR causing deletion of exon 2-7, which results in a functional membrane protein with an extracellular domain mutation. Published data suggest that expression of EGFRvIII on GBMs enhances cell tumorigenicity, invasiveness and therapeutic resistance, [53, 55] , however one recent study suggests that EGFRvIII is not a prognostic factor for GBM and its aggressiveness might be related to other proteins rather than EGFRvIII. [56] A c c e p t e d M a n u s c r i p t 9
EphA2
EphA2 or epithelial cell receptor protein tyrosine kinase, is strongly overexpressed in 60% of GBMs and expressed at a moderate or strong levels in 90-98% of GBM specimens. [57, 58] Expression is detected at low levels on adult proliferating epithelial cells as well as brain tissue and enriched within sites of cell-cell adhesion in normal epithelial cells. [57] As for its role in the malignant phenotype of GBMs, EphA2 is an important regulator of tumor initiation, neo-vascularization, tumor cell migration, invasion and angiogenesis.
HER2
HER2 is a transmembrane tyrosine/kinase receptor also known as erbB-2. It is wellcharacterized tumor antigen which is important for the regulation of cancer growth. For example, it is a prognostic marker in metastatic breast carcinoma, and its overexpression is also associated with a poor prognosis in GBM. HER2 expression level increases with the degree of poor glial cell structural differentiation and other anaplastic related features. [59, 60] In a retrospective study, HER2 expression was detected in 76% of primary GBM cell lines [61] . HER2 expression in pediatric brain tumors was detected in 54% of cases as judged by mRNA/gene profiling analysis. [62] 
IL13Ra2
IL13Rα2 is overexpressed in about 76% of GBMs at a moderate or strong level. [58, 63, 64] A slightly higher percentage (up to 83%) has been reported for pediatric brain A c c e p t e d M a n u s c r i p t 10 tumors, and overexpression is associated with poor prognosis. [62, [65] [66] [67] Two studies have also evaluated the expression of IL13Rα2 in diffuse intrinsic pontine gliomas (DIPGs). [62, 66] In the first study 10 out of 15 DIPGs were positive for IL13Rα2, and in the second study 17 of 28 respectively. GBM CAR targets explored so far, do not meet all the 'ideal target criteria' outlined in the beginning of this section. Thus, there is a continued need to discover additional GBM antigens that can be targeted with CAR T cells. Genetic engineering approaches that restrict full CAR T-cell activation to site at which two antigens are expressed could potentially increase the pool of targeted antigens. [68] Lastly, the recent development of CARs that allow the targeting of HLA/peptide complexes, containing peptides derived from intracellular proteins, should also increase the array of potential antigens including BIRC5 (survivin) and/or mutated IDH1.
4.
Pre-clinical studies with CAR T cells In an effort to more closely mimic the interactions of the infused CAR T cells with resident immune cells, investigators have also started to explore the use of immune competent animal models to evaluate GBM-targeted CAR T cells. Murine EGFRvIII-CAR T cells were evaluated in an immune competent syngeneic model in which glioma cells were genetically modified to express EGFRvIII.
[77] The anti-glioma activity of
EGFRvIII-CAR T cells was dependent on lymphodepletion mice prior to T-cell infusion.
In addition, glioma-bearing mice that were cured by EGFRvIII-CAR T cells were resistant to re-challenge with parental, EGFRvIII-negative glioma cells, indicating the development of host immunity against other glioma-associated antigens.
[77] CD70-CAR T cells have also demonstrated potent anti-tumor activity in an immune competent syngeneic mouse model of glioma. [38] In summary, preclinical studies with CAR T cells targeting GBMs have shown significant anti-glioma activity, which led to Phase 1 testing of IL13Rα2-(NCT02208362), HER2-
NCT02209376, NCT02664363, NCT02844062), and EphA2-CAR (NCT02575261) T
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Clinical studies with CAR T cells
The first clinical study used autologous CD8-positive T-cell clones that were genetically modified to express a first generation IL13Rα2-CAR with an IL13 mutein as an antigen binding domain, the hygromycin gene for selection, and the Herpes Simplex Virus Lack of efficacy is most likely multifactorial, including heterogeneous antigen expression, limited T-cell homing to GBM sites, and the immunosuppressive TME.
Among these, the immunosuppressive TME is considered a major impediment, [17, 18] and we will therefore focus on it in the next section. hampers T-cell metabolism and results in nutrient deprivation. [86] Improving the therapeutic benefit of CAR T cells for brain tumors will most likely require additional modifications to strengthen them against this hazardous environment (Figure 2) .
Improving CAR T cell therapy for GBM

Several genetic modifications have been explored to make CAR T cells less susceptible
to TME-mediated immunosuppression, which we describe in detail below. Specifically, we will focus on (1) transgenic expression of cytokines and cytokine receptors, (2) dominant negative and chimeric switch receptors, and (3) genetic approaches to overcome checkpoint blockade.
Transgenic expression of cytokines and/or cytokine receptors
Providing CAR T cells with pro-survival cytokines can fortify them against the immunosuppressive microenvironment. Transgenic expression of IL-7, IL-12, IL-15, and endodomain. [102] Clearly, this approach could be extended to other inhibitory cytokines present in the TME of GBMs such as IL-10.
IL18 have been explored with promising results. CAR T cells can be engineered to
Genetic approaches to overcome checkpoint blockade
The immune check point programmed cell death protein ligand 1 (PD-L1) is expressed in the majority of GBMs, with higher expression correlating with glioma grade. [103] [104] [105] Checkpoint antibodies conferred a T cell-dependent survival advantage in an orthotopic mouse model of glioma. [106] However, the clinical experience with checkpoint blockade for GBM has been disappointing unless the GBM is deficient in mismatched mismatch repair (MMR) genes. [107, 108] While lack of efficacy of checkpoint blockade monotherapy is multifactorial, the blood brain barrier (BBB) is most likely a contributing factor based on the experience with other GBM-targeted MAb therapies. Genetic modification of T cells to render them resistant to checkpoint inhibition might be one strategy to address this problem.
Several T-cell intrinsic methods of disrupting the PD-1/PD-L1 axis have been shown to enhance CAR T-cell efficacy, including genetic disruption of PD-1 using CRISPR/Cas9, [109] secretion of a PD-1 antibody, [110] expression of a dominant negative PD-1 receptor, [111] or expression of a chimeric switch receptor that combines the extracellular domain of PD-1 with the intracellular signaling domain of CD28 in order to convert an inhibitory signal into a co-stimulatory one. [112, 113] Each of these approaches yielded increased survival times compared with adoptive T-cell transfer where PD-1-mediated immunosuppression was not inhibited.
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In conclusion, genetic approaches to enhance CAR T-cell function have shown promising results in preclinical studies, but so far have not been tested in clinical studies. Clearly, while we have here focused on describing three strategies, others are being actively explored. In addition, the highlighted approaches, like CRISPR/Cas9 gene editing could be applied to other targets.
Conclusions
The first preclinical CAR T-cell therapy study targeting IL13Rα2-positive GBM was Novel antigens are continued to be discovered. For example, since the original submission of this manuscript, targeting chondroitin sulfate proteoglycan 4 with CAR T cells for glioma has been described. [114] In addition to antigen discovery it will be critical to refine current strategies to target multiple antigens. This will be important not only to prevent antigen loss variants, but also to allow targeting of 'antigen patterns' present on glioma cells, potentially increasing the repertoire of targetable antigens.
However, the repertoire of 'common shared antigens' is most likely limited. One approach to 'tap into private neoantigens' expressed by glioma [115] is to optimize the ability of CAR T cells to induce antigen spreading. Antigen spreading, the induction of immune responses against 'non-targeted antigens', correlates with the clinical activity of cancer vaccines, [116] and also has been demonstrated post cell transfer of a single Tcell clone. [117] Lastly, besides targeting glioma cells with CAR T cells, we believe that it might be critical to target supporting stromal cells with CAR T cells for their optimal clinical efficacy. [118] As for solid tumor CAR T-cell therapy, the immunosuppressive tumor microenvironment is a significant hurdle. Current preclinical studies have mainly focused on xenograft models, which do not recapitulate the immunosuppressive tumor microenvironment. For example, transgenic expression of cytokines enhance the anti-glioma activity of CAR T cells. [72] However, it will be critical to evaluate this and other approaches in immune In addition, to optimizing glioma cell recognition, and improving CAR T-cell function within the hostile glioma microenvironment, the optimal route of CAR T-cell delivery needs to be further refined. Currently, intravenous, intratumoral, and intraventricular routes are being explored. While the best of route delivery most likely depends on the clinical scenario, genetic engineering of T cells has the potential to improve T-cell migration to tumor sites, [120, 121] penetration of tumor masses, [122] and/or migration through the blood brain barrier.
Besides 'preclinlcal optimization' of CAR T-cell therapies, it will critical to improve our ability to track T cells post infusion, and monitor their antiglioma activity in glioma patients. While proof-of-principle studies with PET imaging have shown promise, these studies have relied on genetically modifying T cells with HSV-tk, an immunogenic protein. [79, 123] Thus, there is an urgent need to develop novel approaches that would enable us to track CAR T cells post infusion. Assessment of the anti-glioma activity of immunotherapies by imaging using standard response criteria is difficult. In this regard, the Response Assessment for Neuro-Oncology working group published their A c c e p t e d M a n u s c r i p t 23 recommendation for immunotherapy studies. [124] However, these criteria were developed based on results of vaccine studies, and at present it is not clear if these criteria require further modifications for CAR T-cell therapies. Besides imaging, the use of circulating biomarkers hold the promise to improve our ability to assess the antiglioma activity of CAR T cells. [125] In addition, these biomarkers might also shed light if CAR T cells are able to reverse the immunosuppressive environment induced by glioma.
Cancer therapeutics rely on combinatorial strategies. Thus, combining CAR T-cell therapies with other therapeutic approaches will most likely be key for their success.
Besides other immunotherapeutic approaches such as checkpoint blockade and vaccines, epigenetic modifiers, radiation, oncolytics, and drugs that alter the metabolism of cancer cells should be explored.
In conclusion, we believe that immunotherapy for GBM holds the promise to improve outcomes for patients affected by this devastating disease. While this review has focused on cell therapy with genetically modified T cells, other approaches are actively being explored including cell therapies with (1) conventional T cells, [126] (2) T cells that are genetically modified to express TCRs, [127] and (3) 
5-year view
Over the next 5 years we are optimistic that CAR T-cell therapies will have an impact on the outcome of GBM patients. To benefit GBM patients, CAR T cells most likely need to be further genetically modified to enhance their effector function, or combined with other targeted approaches including vaccines, MAbs, or small molecules. Critical for advancing this field will be the development of preclinical animal models that allow us to study the interactions on adoptive transferred CAR T cells, tumor cells, and resident immune cells. Lastly, performing carefully crafted correlative studies in early phase clinical studies will be the key to advance the field of CAR T-cell therapy for GBM.
Key issues
• Currently, there is a limited array of targetable GBM antigens and their expression is heterogeneous
• CAR design is empiric requiring careful optimization for the targeted antigens 
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